cas 86770-80-1|| where to buy 3,3-difluorocyclobutane-1-carbonitrile

Product Name:3,3-difluorocyclobutane-1-carbonitrile

IUPAC Name:3,3-difluorocyclobutane-1-carbonitrile

Packing Unit	Available Stock	Price($)
CM108791-10g	in stock	Ůƴǟ
CM108791-25g	in stock	ǎŌǸŮ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 86770-80-1 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:86770-80-1; Molecular Formula:C5H5F2N; Melting Point:-; Smiles Code:N#CC1CC(F)(F)C1; Density:

: Catalog Number:CM108791; Molecular Weight:117.1; Boiling Point:; MDL No:MFCD10001482; Storage:Store at 2-8°C.

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: Cyclanes; Cyclanes are secondary metabolites that can be found in plants, and are also biochemicals that can be used in medicine. Cyclanes are found in pine trees, and are used in the making of plastics. Cyclenes are found in cinnamon, and have antifungal properties.

: Fluorinated compounds; Fluorinated compounds refers to organic or inorganic compounds containing fluorine.

: Ivosidenib; Tibsovo (ivosidenib tablets) is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). Tibsovo is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation.
Fifth approved indication for Tibsovo solidifies Servier’s leadership in mutant IDH inhibition.